Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes

Talaviya, Praful A.; Saboo, Banshi; Dodiya, Hardik; Rao, Subba; Joshi, Shashank; Modh, Vipul B.; Ghadiya, Sneha V.

doi:10.1016/j.dsx.2015.09.021

Cited by 16 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study conducted by Talaviya et al alpha-glucosidase inhibitors prescribed as an add-on therapy with metformin and sulfonylureas in uncontrolled obese and overweight patients of Type 2 DM provide desired glycemic control, improvement in lipid profile, and decreases in body weight [11]. Metformin + alpha-glucosidase inhibitors (11.56%) prescribed highest in our study.…”

Section: Geetha and Shanmugasundharammentioning

confidence: 86%

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

Geetha¹,

Shanmugasundharam²

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: The aim of the study was to assess the prescribing pattern of antidiabetic drugs in Type 2 diabetes outpatients visiting to Diabetes Centre, Chennai.Methods: A prospective study was carried out by evaluating 115 prescriptions of antidiabetic drugs over the period of 4 months to assess the prescribing pattern of antidiabetic drugs and also drugs used for other complications of Type 2 DM.Results: Totally, 115 patients were evaluated, 58 were of male and 57 were of female. An average number of drugs per encounter were found to be 4.47. An average number of antidiabetic drugs were found to be 2.56. In this study, the most commonly prescribed oral hypoglycemic drug class as single-drug regimen was that of alpha-glucosidase inhibitors (16.326%), dipeptidyl peptidase-4 (DPP-4) inhibitors (14.62%), biquanides (12.9%), thiazolidine diones (9.8%), sulfonyl urea (7.82%) and meglitinides (2.38%), and in multi drug regimen metformin + alpha-glucosidase inhibitors (11.56%) were commonly prescribed. Conclusion:Most commonly used drug was alpha-glucosidase inhibitors, followed by DPP-4 inhibitors and biguanides. All the patients received combination therapy to achieve the glycemic control.

show abstract

Section: Geetha and Shanmugasundharammentioning

confidence: 86%

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

Geetha¹,

Shanmugasundharam²

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Moreover, long-term use of these drugs also leads to some gastrointestinal side effects, including diarrhea and flatulence [ 14 , 15 ]. This situation has encouraged the authors to develop more efficient and safer α-glucosidase inhibitors [ 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-α-Glucosidase, SAR Analysis, and Mechanism Investigation of Indolo[1,2-b]isoquinoline Derivatives

Liu

et al. 2023

Molecules

View full text Add to dashboard Cite

To find potential α-glucosidase inhibitors, indolo[1,2-b]isoquinoline derivatives (1–20) were screened for their α-glucosidase inhibitory effects. All derivatives presented potential α-glucosidase inhibitory effects with IC50 values of 3.44 ± 0.36~41.24 ± 0.26 μM compared to the positive control acarbose (IC50 value: 640.57 ± 5.13 μM). In particular, compound 11 displayed the strongest anti-α-glucosidase activity, being ~186 times stronger than acarbose. Kinetic studies found that compounds 9, 11, 13, 18, and 19 were all reversible mix-type inhibitors. The 3D fluorescence spectra and CD spectra results revealed that the interaction between compounds 9, 11, 13, 18, and 19 and α-glucosidase changed the conformational changes of α-glucosidase. Molecular docking and molecular dynamics simulation results indicated the interaction between compounds and α-glucosidase. In addition, cell cytotoxicity and drug-like properties of compound 11 were also investigated.

show abstract

“…[16][17][18][19][20] Voglibose, a potent competitive inhibitor of intestinal α-glucosidase, delays digestion and absorption of dietary polysaccharides, resulting in effective control of PPG excursions, HbA1c levels, and weight gain. [21][22][23][24][25] Usually, voglibose is administered as 0.2 mg thrice daily before each meal, but the dosage can be increased to 0.3 mg in cases of aggravated PPG response. 22,26 Voglibose has been considered safe (due to poor absorption after oral use) and effective as a monotherapy or a combination therapy.…”

Section: Introductionmentioning

confidence: 99%

“…22,26 Voglibose has been considered safe (due to poor absorption after oral use) and effective as a monotherapy or a combination therapy. 23,[27][28][29][30][31][32][33] In one study, voglibose was found to be effective in lowering daily glycemic excursions, HbA1c, and plasma glucose levels and also in improving insulin sensitivity in T2DM patients. 34 In clinical management, physicians usually prefer to prescribe combination therapies instead of a monotherapy, particularly if the target glycemic goal is not achieved with monotherapy.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose

Kasthuri

Poongothai

Anjana

et al. 2021

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Purpose: To determine the effect of Voglibose add-on therapy on daily glycemic excursions (using FreeStyle ® Libre Pro™, a Flash glucose monitoring system) in Indian patients with type 2 diabetes (T2DM) receiving a stable dose of metformin (Met) or metformin+sulfonylurea (Met+SU). Patients and Methods: T2DM patients with glycosylated hemoglobin (HbA1c) >7.0% and at least two postprandial excursions > 140 mg/dL (within 2 hours of meal) during the screening phase (visit 1/day-14±2), were enrolled in this prospective, multi-centre interventional study. The patients were randomized at visit 2 (Day 0±2) to receive Voglibose 0.2 mg or 0.3 mg tablets (BID/TID) as add-on therapy to Met and Met+SU. All

show abstract

Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes

Cited by 16 publications

References 10 publications

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

Anti-α-Glucosidase, SAR Analysis, and Mechanism Investigation of Indolo[1,2-b]isoquinoline Derivatives

Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose

Contact Info

Product

Resources

About